Severe COVID-19-related Pneumonia Seven Years after Heart Transplantation

  • Taniguchi Gentaro
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Matsushima Shouji
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Fujino Takeo
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan Department of Advanced Cardiopulmonary Failure, Graduate School of Medical Sciences, Kyushu University, Japan
  • Hashimoto Toru
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Shinohara Keisuke
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Kisanuki Hiroshi
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Misumi Kayo
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Katsuki Shunsuke
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan
  • Shiose Akira
    Department of Cardiovascular Surgery, Graduate School of Medical Sciences, Kyushu University, Japan
  • Abe Kohtaro
    Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Japan

Search this article

Description

<p>A 67-year-old man on intense immunosuppressive therapy after heart transplantation for end-stage hypertrophic cardiomyopathy 7 years ago developed severe dyspnea and was admitted to our hospital. His serum severe acute respiratory syndrome coronavirus 2 antigen test was positive, and he was diagnosed with coronavirus disease 2019 (COVID-19)-related pneumonia. He was started on ventilatory management for severe respiratory failure and remdesivir for COVID-19, with careful adjustment of immunosuppressive drugs. However, unexpectedly prolonged muscle weakness necessitated transfer to a rehabilitation facility. Although the COVID-19 pandemic has subsided, it is still considered a risk in post-transplant cases. Infection control is considered critical in heart transplant recipients, especially in those receiving intensified immunosuppressive drugs. </p>

Journal

  • Internal Medicine

    Internal Medicine 64 (12), 1867-1871, 2025-06-15

    The Japanese Society of Internal Medicine

References(19)*help

See more

Details 詳細情報について

Report a problem

Back to top